AJTMH ASTMH MEMBERSHIP INFORMATION: astmh@astmh.org
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med., s1-25(3), 1945, pp. 217-223
Copyright © 1945 by American Journal of Tropical Medicine

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smithburn, K. C.
Right arrow Articles by Mahaffy, A. F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Smithburn, K. C.
Right arrow Articles by Mahaffy, A. F.

Immunization Against Yellow Fever

Studies on the Time of Development and the Duration of Induced Immunity

K. C. Smithburn AND A. F. Mahaffy1
From the Yellow Fever Research Institute, Entebbe, Uganda,2

1. Protective antibody against yellow fever virus is demonstrable in the serum of rhesus monkeys within 6 or 7 days after inoculation with standard 17D yellow fever vaccine virus.
2. Rhesus monkeys are completely resistant to the inoculation of highly virulent pantropic yellow fever virus within 5 or 6 days after injection of 17D vaccine. This resistance is present prior to the appearance in the serum of demonstrable protective antibody.
3. Protective antibody is demonstrable in man in a high per cent of cases by the 10th day after injection of 17D vaccine and may be present as early as the 7th day.
4. Postvaccination surveys of immunity were made in persons inoculated in Africa with 17D vaccine prepared in New York, and revealed the following:
a. 92.2 per cent of military personnel sampled 1 to 22 months after vaccination exhibited protective antibody.
b. 90 per cent of civilians inoculated in Kenya exhibited protective antibody in their sera 23 to 36 months after receiving the vaccine.
c. More than 90 per cent of persons vaccinated in Uganda had protective sera after 3 years, and there was no decline in the incidence of immunity during the third year.
d. The percentage of children who became immune as the result of inoculation was as great as that in adults, and the antibody response was equally well maintained.

Received April 11, 1945.
1 Staff Members of the International Health Division, Rockefeller Foundation.


2 This Institute is supported jointly by the Medical Department of the Uganda Protectorate and the International Health Division of The Rockefeller Foundation.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1945 by the American Society of Tropical Medicine and Hygiene.